Literature DB >> 18398358

Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.

John O Mason1, Milton F White, Richard M Feist, Martin L Thomley, Michael A Albert, Tarek O Persaud, Jacob J Yunker, Rachel S Vail.   

Abstract

PURPOSE: To report the incidence of acute endophthalmitis as a complication of intravitreal bevacizumab (Avastin) (IVB) injection in a tertiary vitreoretinal group practice.
METHODS: A retrospective chart review of 5,233 consecutive eyes that underwent IVB injection at Retina Consultants of Alabama (RCA) from October 1, 2005, to August 31, 2007, was performed to identify cases of acute endophthalmitis.
RESULTS: During the 23-month study interval, the overall incidence rate of postinjection endophthalmitis was 0.019% (1/5,233). In the single case of acute endophthalmitis, bacterial cultures revealed coagulase-negative Staphylococcus (CNS) species. Visual acuity after treatment for endophthalmitis was improved (baseline 4/400) to 20/400 at two months after the initial IVB injection.
CONCLUSIONS: Acute endophthalmitis is a rare potential complication of IVB. Prophylaxis with topical povidone-iodine and adherence to aseptic technique minimizes the risk of postinjection infection. SUMMARY STATEMENT: A retrospective review of 5,233 consecutive intravitreal injections of bevacizumab (Avastin) revealed only a single case of acute endophthalmitis. Adherence to aseptic technique and the use of povidone-iodine prophylaxis minimizes the risk of postinjection intraocular infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398358     DOI: 10.1097/IAE.0b013e3181633fee

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  43 in total

Review 1.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

2.  Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.

Authors:  Murilo W Rodrigues; José A Cardillo; André Messias; Rubens C Siqueira; Ingrid U Scott; Rodrigo Jorge
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-23       Impact factor: 3.117

3.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

4.  Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.

Authors:  Hiroyuki Shimada; Takayuki Hattori; Ryusaburo Mori; Hiroyuki Nakashizuka; Kyoko Fujita; Mitsuko Yuzawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

5.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

6.  Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Authors:  Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman
Journal:  Arch Ophthalmol       Date:  2009-12

7.  Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.

Authors:  Jeff H Pettey; Mark D Mifflin; Randall J Olson
Journal:  J Ocul Pharmacol Ther       Date:  2015-08-19       Impact factor: 2.671

8.  Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.

Authors:  D A M Lyall; A Tey; B Foot; S T D Roxburgh; M Virdi; C Robertson; C J MacEwen
Journal:  Eye (Lond)       Date:  2012-10-12       Impact factor: 3.775

9.  Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis.

Authors:  Ludimila L Cavalcante; Milena L Cavalcante; Timothy G Murray; Michael M Vigoda; Yolanda Piña; Christina L Decatur; R Prince Davis; Lisa C Olmos; Amy C Schefler; Michael B Parrott; Kyle J Alliman; Harry W Flynn; Andrew A Moshfeghi
Journal:  Clin Ophthalmol       Date:  2010-05-25

10.  Case of endophthalmitis following intravitreal injections of bevacizumab.

Authors:  Shinya Komori; Akira Sawada; Tsutomu Oguni; Kiyofumi Mochizuki; Kiyofumi Ohkusu
Journal:  Clin Ophthalmol       Date:  2010-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.